

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 990 450 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
05.04.2000 Bulletin 2000/14

(51) Int Cl.7: **A61M 37/00, A61K 9/00,
A61K 9/20**

(21) Application number: **99307736.1**

(22) Date of filing: **30.09.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Kenison, Dale C.**
Overland Park, KS 66213 (US)
• **Spurlin, Stanford R.**
Lenexa, KS 66215 (US)

(30) Priority: **30.09.1998 US 163646**

(74) Representative: **Powell, Stephen David et al**
WILLIAMS, POWELL & ASSOCIATES
4 St Paul's Churchyard
London EC4M 8AY (GB)

(71) Applicant: **Ivy Animal Health, Inc.**
Overland Park, Kansas 66214 (US)

(54) **Pharmaceutical implants**

(57) A pharmaceutical pellet system (10), which delivers both immediate and long term control of parasite infestation in an animal as part of a single implant procedure, includes an implanter apparatus (12) for subcutaneously implanting parasitocidal pellets (14, 16) in an animal through the bore of a hypodermic needle (22) which is operably coupled to a pellet magazine (18), and a plurality of pellets (14, 16) sized to be implanted

through the needle and positioned in the magazine for selective alignment of a pellet with a needle. The pellets include at least one immediate release parasitocidal agent first dose pellet and at least one extended release parasitocidal agent dose second pellet. The combined pellets are packaged in the magazine in sequential order for simultaneous delivery of an immediate dose and an extended dose as part of a single injection.

EP 0 990 450 A2

Description

[0001] The present invention is broadly concerned with a pellet implant system and in particular one that simultaneously administers both an immediate parasiticidal dosage first component and a long term release parasiticidal dosage of a second component placed in subcutaneous pellets in order to control internal and external parasites in domesticated and wild animals. More particularly, it is concerned with an implanter having a pellet magazine containing parasiticidal pellets with an associated injection needle, as well as structure permitting injection of the pellets from the magazine through the needle for implantation under the skin of a animal. The pellets are formulated to deliver two separate doses simultaneously. The first dose is a parasiticidal dose which is immediately available for absorption. The second dose is a parasiticidal dose which is available for sustained absorption through bioerosion and diffusion over an extended period of time.

[0002] The importance of parasite control in animals used for meat and other agriculture production, recreation and companionship is well recognized. Meat, milk and fiber producing animals, such as suckling, growing, grazing and feed lot cattle, domesticated swine, sheep, goats, poultry and companion animals such as horses, dogs and cats all serve as hosts for a large number of internal and external parasites. The presence of such parasites is known to reduce overall production in animals producing meat and other agricultural products. In the case of companion and recreational animals, the presence of parasites can lead to discomfort, impaired health and performance, and even death.

[0003] Wild animal populations infested with parasites may experience substantial harmful effects as well as reduced reproductive efficiency. Such harmful effects are of particular concern in populations of endangered species, since it may impair attempts to reintroduce the species into an environment or to build the species population up to a level which can be easily sustained by natural growth. Endangered mammalian species which are maintained or managed in limited area preserves such as game preserves, animal parks, national parks or wildlife areas as well as zoo animals which are maintained in confined areas, are particularly susceptible to parasite infestation since they inhabit areas substantially smaller than their natural habitats, with denser populations of both parasites and their animal hosts.

[0004] Implant technology, that is to say, subcutaneous implant of pharmaceuticals and medical devices, is now well accepted and widespread in the fields of animal health and production enhancement and human health. Many types of biologically active compounds, including hormones, vitamins, antibiotics, antiinflammatory agents, vaccines and biocides are administered as solid compressed pellets which are injected by an implanter equipped with a hypodermic needle. The needle is used to make a small self-sealing and noncoring im-

plant-receiving puncture beneath the skin at a suitable location on the body of the animal. Small pellets of the bioactive compound are forced through the needle and left under the skin as the needle is removed. The ears are a preferred site for pellet implantation in livestock such as cows, pigs and sheep. Implanted ears are commonly discarded in slaughtering, so that no unabsorbed pellet residue will end up in food products intended for consumption by humans or domestic animals.

[0005] The pellets are normally implanted in farm animals while the animal is confined in a chute. An ear is grasped in one hand, and an implanter device having a large hypodermic needle is used to puncture the hide and subcutaneously inject a pellet dose into an implant-receiving puncture. Implantation must be done carefully to ensure that the pellets are properly placed and that no portion of the pellet remains extending from the puncture outside the hide. The procedure must also be carried out quickly since the animals are not entirely cooperative and may shake their heads to free the held ear.

[0006] U.S. Patent No. 5,522,797 (hereinafter "the '797 patent"), and entitled Slide Action Veterinary Implanter, which patent is hereby incorporated by reference, discloses an implanter which employs a slide action mechanism to retract an impeller, store an impeller driving force in a spring in cooperation with a latch mechanism, reset a trigger, and advance a pellet magazine, all by a single trigger actuated reciprocation of the slide mechanism. Operation of the trigger also forces the pellets from the magazine through the needle and under the skin of the animal.

[0007] Efficient implanters such as that taught in the '797 patent permit rapid sequential injection of many animals in a single session and make implant technology particularly well-suited for administration of parasitocides while the animals are confined for ear tagging, branding, veterinary procedures or the like. Even where only a single animal is to be treated, implantation offers a particularly safe method for administering certain biocides, so as to allow a user to avoid biocides that could be toxic if ingested by the animal, for example by licking off residue left on its own hide or fur or on that of another animal following treatment by dipping, spraying or dusting.

[0008] A number of effective compounds are available for internal and external parasite control, including the polyketide avermectins, the milbemycins and milbemycin oximes, fenbendazole and lufeneron. The most commonly used avermectins are ivermectin, doramectin, moxidectin, eprinomectrin and abamectin. However, such parasiticidal compounds have not previously been available in implantable pellet formulations which provide for immediate as well as extended release of the parasiticide.

[0009] Previous avermectin and milbemycin implants such as disclosed by Hepler in PCT application WO 9625852 and by Wallace in U.S. Patent No. 4,847,243 do not provide prolonged controlled release of the par-

asiticide dose. Consequently, additional parasiticial pellets must be periodically implanted in host animals to treat parasites in the immediate environment of the host animal.

[0010] This requirement for periodic readministration is not only cumbersome and inefficient, it increases the likelihood that a dose will be delayed or missed altogether and that parasites endemic to the environment will reinfest the host animal. Moreover, each such procedure subjects the animal to stress and risk of infection at the injection site.

[0011] A variety of techniques are currently employed to obtain sustained release of parasiticides. Oral boluses are formulated in double walled cylinders, with layers of racemates of active ingredients, with outer and inner layers having polymer coatings, with wax and fat to retard dissolution, and with a heat responsive carriers.

[0012] While such measures provide for sustained release of parasiticides over many hours, they do not obviate the need for periodic redosing. Effective parasite control requires prolonged sustained release for periods of up to several months in order to interrupt the parasite life cycle in the environment of the host animal.

[0013] Accordingly, there is a need for a system which delivers subcutaneously pellet implants of varying controlled release parasiticial dosages to provide immediate as well as sustained release of the parasiticide for a period of up to several months, and which does so without requiring periodic redosing.

[0014] The present invention resolves the problems previously outlined and provides a greatly improved parasiticial pellet system which delivers separate doses of both immediate and long term control of parasite infestation in an animal as part of a single implant procedure wherein the immediate dose is sufficient to kill pests already present in the animal and the long term dose is sufficient to prevent reinfestation.

[0015] Broadly speaking, the pellet system includes an implanter apparatus for subcutaneously implanting parasiticial pellets in an animal through the bore of a hypodermic needle which is operably coupled to a pellet magazine, and a plurality of pellets sized to be implanted through the needle and positioned in the magazine for selective alignment of a pellet with the needle. The pellets include at least one immediate release parasiticial agent first dose pellet and at least one extended release parasiticial agent dose second pellet. The combined pellets are packaged in the magazine in an individual dosing chamber for simultaneous delivery of an immediate dose and an extended dose as part of a single injection.

Advantageously, the system permits both immediate and sustained release of an effective dose of the parasiticial agent, in order to control present parasite infestation and release sufficient agent over time to prevent reinfestation for a period of up to about 150 days. The immediate and sustained release agents may be the same or different parasiticial agents with the principal

difference between the agents being that the immediate agent is formulated to completely release into the system of the animal very quickly after implanting to provide a sufficient systemic amount of the immediate agent to kill pests that are currently in the animal and the sustained agent is formulated in a slow release matrix that slowly releases the sustained agent over a comparatively long time, for example about 150 days, in a sufficient amount to systemically prevent reinfestation of the animal.

[0016] The principal objects and advantages of the present invention include: providing a multicomponent parasiticial pellet system; providing a pellet system for immediate as well as sustained delivery of a parasiticide in order to kill both internal and external parasites present on an animal and which may reinfest the animal in the future; providing a pellet system which includes an implanter apparatus for subcutaneously injecting pellets in an animal through the bore of a hypodermic needle which is operably coupled to a pellet magazine and simultaneously introduces separate immediate and extended release parasiticial pellet doses; providing such a system and method which permits injection of predetermined doses of each of a parasiticide for immediate release and a parasiticide for extended release in a single injection; providing such a system and method which permits subcutaneous injection of both an immediate release parasiticial dose and an extended release parasiticial dose; providing such a system and method which permits an operator to selectively inject an extended release parasiticial dose into the needle; providing such a system and method which permits serial injection of large numbers of animals in a single session; providing such a system and method which may employ a wide range of parasiticial agents for use in control of infestation; providing such a system and method which is simple and efficient and economical to manufacture, which effectively prevents reinfestation of the animal for a period of up to about 150 days and which is particularly well-adapted for its intended purpose.

[0017] Other objects and advantages of this invention will become apparent from the following description taken in conjunction with the accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention.

[0018] The drawings constitute a part of this specification and include exemplary embodiments of the present invention and illustrate various objects and features thereof.

[0019] Figure 1 is a fragmentary perspective view of a cow, an implanter apparatus in accordance with the present invention, and an apparatus operator.

[0020] Fig. 2 is an enlarged, fragmentary cross-sectional view, taken along line 2-2 of Fig. 1, illustrating a hypodermic needle with pellets inside the needle being inserted into an ear of the cow.

[0021] Fig. 3 is an enlarged, fragmentary cross sectional view similar to Fig. 2, illustrating subcutaneous

placement of a stack of pellets by the implanter into the ear of the cow.

[0022] As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriately detailed structure.

[0023] Referring now to the drawing, the reference numeral 10 represents a pellet implantation system in accordance with the invention. The implantation system 10 broadly includes a slide action implanter apparatus 12 which is used to implant solid form bioactive compounds in various formulations, such as immediate release compressed pellets 14 and extended release compressed pellets 16 (Fig. 2) from a magazine strip 18 into an animal 20 through a hypodermic needle 22. The needle 22 is utilized by an operator 24 to create an opening 26 that produces an implant receiving puncture 28 in the animal 20.

[0024] A suitable implanter apparatus 12 is illustrated and described in detail in the '797 patent, and generally includes a housing 30 having a finger grip 32 with a trigger assembly 34 pivotally mounted therein. An impeller 36 is slidably mounted within the housing 30 in alignment with an interior bore 38 of the needle 22 and aligned chambers 40 of the loaded pellet magazine strip 18. The needle 22 is used to puncture through skin or hide 42 of an animal's ear 44 at the opening 26, and the trigger 34 is squeezed toward the grip 32 of the housing 30 to initiate injection of the pellets 14 and 16 and so as to cause the impeller 36 to be urged through the magazine chamber 40 and needle bore 38, thereby forcing the pellets 14 and 16 through the bore 38 of needle 22 and into the puncture 28 in the ear 44.

[0025] Each magazine strip 18 of the implanter 12 typically contains multiple parallel aligned pellet doses stored in corresponding pellet chambers 40, which are connected by interconnecting webs 46. The chambers 40 are slightly conical in shape and are arranged in a side-by-side parallel relation. The chambers 40 may have internal frictional formations such as beads or posts (not shown) to retain the pellets 14 and 16 therein prior to insertion and which can be easily bypassed by application of pressure to the trigger 34. A plurality of strips 18 can be connected in end-to-end relation to increase the implanting capacity before the implanter 12 requires reloading. When the pellets 14 and 16 in an individual magazine strip 18 are exhausted, the empty strip 18 can be detached from the remaining strips 18 located in the implanter 12 and discarded.

[0026] In the present embodiment, each pellet chamber 40 is loaded with a single immediate release parasiticide agent dose pellet 14 and five extended release

parasiticide agent dose pellets 16. The pellets 14 and 16 are composed of an effective amount of one or more parasiticide agents, formed into a compressed pellet in conjunction with one or more excipients.

[0027] A wide range of active ingredients may be employed as parasiticide agents, for example, the polyketide avermectins, such as ivermectin, doramectin, moxidectin, eprinomectrin and abamectin, the milbemycins and milbemycin oximes, fenbendazole and lufenuron. As used herein the term parasiticide is intended to include parasiticides as noted above and other compositions that operably function under the present invention like parasiticides in combating and preventing reinfestation by internal and external parasites and which may be used internally in the particular species of animal to be treated by the invention. It is noted that the amount of parasiticide agent required to produce the desired treatment varies with respect to the species and size of the animal to be treated. For example, when treating cattle the immediate release pellet preferably contains between about 25 and 125 milligrams of ivermectin and the sustained released combined pellets contain between about 50 and 175 milligrams of ivermectin. Parasiticide agents having extended circulatory half-lives, such as ivermectin, are particularly preferred.

[0028] The pellets are uniquely and separately formulated so as to be biodegradable in the target animal and to control release of the parasiticide at different rates. The extended release pellets 16 are formulated to combine an effective dose of a parasiticide agent such as ivermectin, with binding agent excipients that lengthen the implant delivery period by extending pellet 16 integrity and limiting pellet hydration by extracellular fluid entry into the pellet 16. In this manner, the extended pharmacokinetics of the parasiticide agent, delayed bioerosion of the pellet, and delayed diffusion of the agent dose cooperatively result in an extended release pellet which makes available for absorption an effective dose of parasiticide compound over a period of up to 150 days.

[0029] Any of a number of excipients may be employed in the extended release pellets 16, including lactose, polyethylene glycol, as sold under the trademark Carbowax®, by Union Carbide, magnesium stearate, cellulose and its derivatives, especially ethylcellulose as sold under the trademark Ethocel® by Dow, polymeric supports, binders and coloring agents.

[0030] The immediate release pellets 14 make the parasiticide available for absorption into the bloodstream of the animal immediately and may include the previously listed excipients as well as disintegration aids such as magnesium stearate and croscarmellose sodium, especially as sold under the trademark Ac-Di-Sol® by FMC and microcrystalline cellulose, especially as sold under the trademark Avicell® by FMC.

[0031] Each intermediate release pellet 14 is formulated to dissolve and enter the animal's blood system (systemically) within a few days, preferably within hours

of injection. The extended release pellets 16 are formulated to release active parasiticide into the animal's blood system slowly and continuously over a period of many days, for example about 150 days, in order to sustain sufficient parasiticide systemically in the animal being treated to prevent reinfestation by undesirable pests.

[0032] The compressed pellets 14, 16 can be produced inexpensively and in large quantities by a variety of conventional manufacturing equipment.

[0033] In the illustrated embodiment, one pellet 14 incorporates an immediate release parasiticide dose and the other five pellets 16 incorporate an extended release parasiticide dose. It is foreseen that the number of pellets within an individual dosing chamber 40 within a magazine 18 for each release formulation within may vary, depending on the desired dose of parasiticide to be delivered. As an example, the extended release pellets 16 may number one or many, such as the illustrated five.

[0034] Each magazine chamber 40 is prefilled with a preferred number of discrete pellets 14 and 16, each containing a parasiticide dose in a compressed pellet formulation designed respectively for immediate and extended release, the chamber 40 containing at least one immediate release pellet 14 and one extended release pellet 16. The magazine strip 18 is preferably loaded onto implanter housing 30 in an orientation so that the immediate release parasiticide pellet 14 will be delivered first, followed by the extended release parasiticide pellets 16.

[0035] In use, an operator grasps the implanter 12 by the grip 32 and urges the needle 22 into the hide 42 and under the skin of the target animal 20 to make the implant receiving puncture 28. The puncture 28 shown in Fig. 2, is approximately half complete and is complete in Fig. 2. The operator 24 depresses the trigger member 34, thereby propelling a pin 48 of the impeller member 36 forwardly through an aligned magazine chamber 40, forcing the pellets 14 and 16 through the needle bore 38 and into the implant receiving puncture 28. The operator 24 then withdraws the needle 22, leaving the pellets 14 and 16 in the implant receiving puncture 28.

[0036] The bioerodible excipient disintegration aids included in the formulation of immediate release pellet 14 allows the pellet 14 to immediately make available for systemic absorption an effective dose of a parasiticide compound, such as ivermectin. The long circulatory half-lives of such compounds ensures protection of the animal against parasites for up to 30 days. The binders included in the extended release pellets 16 cause delayed bioerosion of the pellets and diffusion of the effective dose of the parasiticide compound for absorption into the bloodstream of the animal over an additional period of up to 120 days. This multicomponent formulation lengthens the pellet delivery period for the parasiticide compound dose so that effective blood levels of the parasiticide compound are maintained for periods of up to 150 days. In this manner, the internal and ex-

ternal parasites of the host animal are eliminated, and the animal is protected from reinfestation until the parasite life cycle in the environment has been interrupted and persistency, that is to say, repeated reinfestation of the animal with parasites endemic to the environment is eliminated.

[0037] Advantageously, the magazine strip 16 may be loaded for selective injection of any number of immediate release pellets 14 or extended release pellets 16 in order to obtain delivery of a selected dosage by each formulation tailored to the species, weight, age or sex in a wide variety of animals. Where a number of pellets of each formulation of pellets 14 and 16 are to be delivered, the pellets may be alternated. In other embodiments, both immediate and delayed release antiparasitic pellets 14 and 16 may be alternated in a stack of pellets of other pharmaceuticals, for delivery through the implant receiving puncture 28.

[0038] The pellet system 10 of the present invention may be employed efficaciously with cows, sheep, swine, goats, poultry, horses, dogs, cats or any other suitable animal, including wild animals and humans.

[0039] The following example is provided for the purpose of illustrating the invention and is not intended to be limiting upon the scope of the claims.

EXAMPLE 1

[0040] A quick release pellet is produced including 100 milligrams of ivermectin in a quick release matrix of lactose and microcrystalline cellulose as a disintegration aid. A set of five sustained released pellets is formulated and formed containing a total of 125 milligrams of ivermectin in a controlled and sustained release matrix of polyethylene glycol. Thereafter, all six pellets are implanted under the skin in the ear of a cow.

[0041] It is to be understood that while certain forms of the present invention have been illustrated and described herein, it is not to be limited to the specific forms or arrangement of parts described and shown.

Claims

1. A method for providing immediate and long term control of parasite infestation in an animal; said method comprising:

- (a) providing an implanter apparatus for implanting parasiticide pellets in an animal through the bore of a hypodermic needle which is operably coupled to a pellet magazine;
- (b) loading the pellet magazine with an immediate release parasiticide agent pellet dose and an extended release parasiticide agent pellet dose;
- (c) inserting the hypodermic needle under the skin of the animal and injecting the immediate

- release pellet dose and the extended release pellet dose into the animal; and
 (d) withdrawing the hypodermic needle from under the skin of the animal so as to leave the immediate release pellet dose and extended release pellet dose beneath the skin. 5
2. The method according to claim 1 including providing a plurality of discrete pellet doses.
3. The method according to claim 2 including providing at least one discrete immediate release dose in a first pellet and at least one discrete extended release dose in a second pellet. 10
4. The method according to claim 1 including:
- (a) inserting the hypodermic needle under the skin of the animal and injecting an immediate release pellet dose; and while 20
- (b) maintaining the hypodermic needle in place under the skin of the animal, sequentially injecting an extended release pellet dose.
5. In a method of administering a subcutaneous implant to an animal, the improvement comprising: 25
- (a) injecting an implant for retention under the skin of the animal including an immediate release parasiticide agent dose and an extended release parasiticide agent dose in a single injection. 30
6. A method for providing immediate and sustained parasiticide release in an animal, comprising:
- (a) providing an implanter apparatus for implanting pharmaceutical pellets in an animal through the bore of a hypodermic needle which is operably coupled to a pellet magazine; 35
- (b) loading the pellet magazine with an immediate release parasiticide agent pellet dose and an extended release parasiticide agent pellet dose; 40
- (c) inserting the hypodermic needle under the skin of an animal and selectively injecting the immediate release pellet dose; 45
- (d) maintaining the hypodermic needle in place under the skin of the animal and also selectively injecting extended release parasiticide agent pellet dose; 50
- (e) withdrawing the hypodermic needle from under the skin of the animal while leaving said pellets beneath the skin of the animal.
7. In an implant adapted for subcutaneous implantation in an animal by an implanter apparatus (12) through the bore of a hypodermic needle (22) which is coupled to a pellet magazine (18), the improvement comprising:
- (a) said implant including a plurality of pellets (14, 16) sized and shaped to be implanted through the needle and positioned in the magazine for selective alignment of the implant with the needle; and
 (b) the pellets including an immediate release parasiticide agent pellet dose and an extended release parasiticide agent pellet dose.
8. The implant according to Claim 7 wherein:
- (a) the pellets (14, 16) are packaged in the magazine (18) in sequential order for delivery of an immediate release parasiticide agent dose in at least one discrete pellet followed by an extended release parasiticide agent dose in at least one pellet for subcutaneous placement in a single injection. 15
9. The implant according to Claim 8 wherein the parasiticide agent dose pellets comprise compositions selected from the group consisting of avermectin, milbemycin, fenbendazole and lufenuron and mixtures thereof.
10. The implant according to Claim 9 wherein the parasiticide agent comprises ivermectin.
11. The implant according to Claim 8 wherein:
- a) each immediate release agent pellet includes a disintegration agent; and
 b) each extended release agent pellet includes a bioerodible matrix.
12. An implant for subcutaneous implantation in an animal comprising:
- (a) at least one discrete immediate release parasiticide agent pellet dose; and
 (b) at least one discrete extended release parasiticide agent pellet dose; all of said pellets being combined in a single unit for implantation side by side into the same site.
13. The implant according to Claim 12 including:
- (a) an excipient and each of said parasiticide agent pellets comprises a composition selected from the group consisting of the avermectin, milbemycin, fenbendazole, lufenuron and mixtures thereof.
14. The implant according to Claim 13 wherein the parasiticide agent comprises ivermectin.
15. The implant according to Claim 12 wherein:
- a) each immediate release parasiticide agent pellet includes a disintegration agent; and
 b) each extended release parasiticide agent

pellet dose includes a bioerodible matrix.

5

10

15

20

25

30

35




40


45

50

55

7





Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 990 450 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
02.08.2000 Bulletin 2000/31

(51) Int Cl.7: **A61M 37/00, A61K 9/00,
A61K 9/20**

(43) Date of publication A2:
05.04.2000 Bulletin 2000/14

(21) Application number: **99307736.1**

(22) Date of filing: **30.09.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Kenison, Dale C.**
Overland Park, KS 66213 (US)
• **Spurlin, Stanford R.**
Lenexa, KS 66215 (US)

(30) Priority: **30.09.1998 US 163646**

(74) Representative: **Powell, Stephen David et al**
WILLIAMS, POWELL & ASSOCIATES
4 St Paul's Churchyard
London EC4M 8AY (GB)

(71) Applicant: **Ivy Animal Health, Inc.**
Overland Park, Kansas 66214 (US)

(54) **Pharmaceutical implants**

(57) A pharmaceutical pellet system (10), which delivers both immediate and long term control of parasite infestation in an animal as part of a single implant procedure, includes an implanter apparatus (12) for subcutaneously implanting parasitocidal pellets (14, 16) in an animal through the bore of a hypodermic needle (22) which is operably coupled to a pellet magazine (18), and a plurality of pellets (14, 16) sized to be implanted

through the needle and positioned in the magazine for selective alignment of a pellet with a needle. The pellets include at least one immediate release parasitocidal agent first dose pellet and at least one extended release parasitocidal agent dose second pellet. The combined pellets are packaged in the magazine in sequential order for simultaneous delivery of an immediate dose and an extended dose as part of a single injection.




Fig. 2.

EP 0 990 450 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 99 30 7736

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A,D	US 5 522 797 A (GRIMM) 4 June 1996 (1996-06-04) * abstract; figures 1-5 *	7,8,12	A61M37/00 A61K9/00 A61K9/20
A	US 5 417 682 A (DONG ET AL.) 23 May 1995 (1995-05-23) * abstract * * column 3, line 39 - column 4, line 7 * * column 6, line 33 - line 51 * * column 6, line 64 - column 7, line 31; figures 1-5 *	7,8,12	
A	EP 0 551 699 A (HYDRO MED SCIENCES) 21 July 1993 (1993-07-21) * abstract * * page 11, line 2 - line 12 * * page 14, line 25 - line 31; figures 1,2 *	7,8,12	
A	EP 0 462 608 A (THERA GESELLSCHAFT FUER PATENTE) 27 December 1991 (1991-12-27) * abstract; claims 1-5 * * page 2, line 33 - line 42 * * page 4, line 19 - line 28 *	7,8,12	
-/--			TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61M A61D A61K
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely : 7-15</p> <p>Claims searched incompletely : 1-6</p> <p>Reason for the limitation of the search: Article 52 (4) EPC - Method for treatment of the human or animal body by therapy</p>			
Place of search THE HAGUE		Date of completion of the search 2 June 2000	Examiner Michels, N
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.92) (PMD/07)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 30 7736

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.CL.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	EP 0 293 066 A (ALZA CORP) 30 November 1988 (1988-11-30) * abstract * * page 12, line 9 - line 21 *	7,9,10, 12-14	
X,P	US 5 874 098 A (SPURLIN ET AL.) 23 February 1999 (1999-02-23) * The Whole Document *	7,8,11, 12,15	
			TECHNICAL FIELDS SEARCHED (Int.CL.7)

EPO FORM 422 (01.02.99) (P4/C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 7736

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-06-2000

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5522797	A	04-06-1996	NONE	
US 5417682	A	23-05-1995	US 5312388 A	17-05-1994
			US 5443459 A	22-08-1995
			US 5531736 A	02-07-1996
			AT 112159 T	15-10-1994
			AU 653793 B	13-10-1994
			AU 1339492 A	07-09-1992
			CA 2098992 A	31-07-1992
			DE 69200476 D	03-11-1994
			DE 69200476 T	02-02-1995
			DK 569534 T	10-04-1995
			EP 0569534 A	18-11-1993
			ES 2065178 T	01-02-1995
			FI 933397 A	29-07-1993
			IE 70328 B	13-11-1996
			JP 6505263 T	16-06-1994
			KR 183058 B	01-05-1999
			MX 9200331 A	01-10-1992
			NZ 241413 A	22-12-1994
			PT 100054 A	29-04-1994
			WO 9213521 A	20-08-1992
			US 5938654 A	17-08-1999
			ZA 9200543 A	28-10-1992
EP 0551699	A	21-07-1993	AU 652984 B	15-09-1994
			CA 2059406 A,C	16-07-1993
			JP 5269760 A	19-10-1993
			AT 140243 T	15-07-1996
			AU 1018292 A	29-07-1993
			DE 69212135 D	14-08-1996
			DE 69212135 T	30-01-1997
EP 0462608	A	27-12-1991	DE 4019617 A	02-01-1992
			AT 142510 T	15-09-1996
			DE 59108169 D	17-10-1996
			ES 2093050 T	16-12-1996
			JP 4231962 A	20-08-1992
			US 5374427 A	20-12-1994
EP 0293066	A	30-11-1988	US 4892778 A	09-01-1990
			AU 619454 B	30-01-1992
			AU 1162588 A	01-12-1988
			CA 1331440 A	16-08-1994
			DE 3880009 A	13-05-1993
			DE 3880009 T	15-07-1993

EPO FORM P0489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 7736

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-06-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0293066 A		GR 3007577 T	31-08-1993
		JP 2683359 B	26-11-1997
		JP 63297319 A	05-12-1988
		KR 9503920 B	20-04-1995
		US 4940465 A	10-07-1990
		ZA 8801449 A	23-08-1988
US 5874098 A	23-02-1999	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82